(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

SHL PHARMA

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

SHL PHARMA

ST13

US500000086398340

Class

10, 40, 42

Filing

86398340

Registration

4907061

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

32

Latest update

03/03/2025

Trademark type

Word

Nice classes

10, 40, 42

Filing date

09/18/2014

Registration date

03/01/2016

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

08/17/2022

Last transaction

03/03/2025

Responsible office

United States Patent and Trademark Office

Status code

702

Official register

Principal Register

Drawing code

4

Owner type

03

Owner location

ZUG, CH

Examiner

LEE RISO, LOKSYE

Law office

L10

Current location

TMEG LAW OFFICE 101

Holders and representatives

Holders

SHL MEDICAL AG
SHL GROUP AB
SHL GROUP AB

Representatives

David M. Frischkorn MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP

Technical classification

Nice Classes

Class 10Class 40Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 10

Medical apparatus and instrumentsinfusion and injection devices for administering drugs

Class 40

Custom assembling of infusion and injection devices for others in the health carepharmaceutical and biotechnology fields

Class 42

Design of manufacturing methods for use in fabrication of infusion and injection devices for administering drugs; product research and development of medical apparatus and instrumentsinfusion and injection devices for administering drugs

Publications

History of USPTO decisions and trademark events.

32 publications found

REM2

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

03/02/2025

NA85

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED

08/17/2022

C15A

REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.

08/17/2022

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

08/16/2022

E815

TEAS SECTION 8 & 15 RECEIVED

02/28/2022

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

03/01/2021

ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

10/17/2018

R.PR

REGISTERED-PRINCIPAL REGISTER

03/01/2016

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

12/15/2015

PUBO

PUBLISHED FOR OPPOSITION

12/15/2015

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

11/25/2015

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

11/06/2015

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

11/05/2015

ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

10/21/2015

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

10/20/2015

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

10/20/2015

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

10/13/2015

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

08/04/2015

GNRT

NON-FINAL ACTION E-MAILED

08/04/2015

CNRT

NON-FINAL ACTION WRITTEN

08/04/2015

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

06/26/2015

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

06/26/2015

ALIE

ASSIGNED TO LIE

06/26/2015

ALIE

ASSIGNED TO LIE

06/16/2015

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

06/08/2015

ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

02/11/2015

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

01/06/2015

GNRT

NON-FINAL ACTION E-MAILED

01/06/2015

CNRT

NON-FINAL ACTION WRITTEN

01/06/2015

DOCK

ASSIGNED TO EXAMINER

01/05/2015

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

09/25/2014

NWAP

NEW APPLICATION ENTERED

09/22/2014

Continuous trademark protection

Get notified about every new filing that threatens SHL PHARMA or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.